| |
Trustee Archive
The term of a prescription drug’s patent is 20 years from the date of a pharmaceutical company’s patent application. Therefore, a generic drug can only be marketed after the brand name drug's patent has expired. A generic drug is a medication created to be the same as an existing approved brand-name drug in dosage, safety, strength, quality and performance. Generic drugs are usually much cheaper than brand name drugs once they reach the market. However, large pharmaceutical companies often pay generic drug makers to delay marketing a generic version of their drug to keep the price of the original medication high. Critics claim this “pay for delay” tactic benefits both brand name and generic drug makers, but is bad for consumers who foot the bill for more than $1 billion in higher drug prices each year. Pharmaceutical companies warn that generic drugs, some foreign-made, may lack the quality assured to consumers by FDA-approved medications. However, researchers who purchased foreign-made pharmaceuticals online and compared them to FDA-approved drugs found these drugs proved to be safe and effective medications.
Pending legislation: S.142 - Preserve Access to Affordable Generics and Biosimilars Act
Sponsor: Sen. Amy Klobuchar (MN)
Status: Senate Committee on the Judiciary
Chair: Sen. Richard Durbin (IL) |
- I oppose reforming current generic drug policy and wish to donate resources to the campaign committee of Leader Charles Schumer (NY).
- I support prohibiting brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. And wish to donate resources to the campaign committee of Sen. Richard Durbin (IL) and/or to an advocate group currently working with this issue.
|
|
| Winning Option
»» No issues were voted |
-
I support prohibiting brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. And wish to donate resources to the campaign committee of Sen. Richard Durbin (IL) and/or to an advocate group currently working with this issue.
|
- Association for Accessible Medicines
If elected as a trustee, Association for Accessible Medicines will be awarded the funds pledged to this issue along with a letter requesting these funds be used to advocate for increasing the manufacture of, and access to, generic prescription drugs.
About: Association for Accessible Medicines promotes and protects access to affordable medicines in trade agreements and represents these interests before the U.S. Trade Representative, the Department of Commerce, Congress, The White House and other stakeholders. AAM advocates for driving down the costs of existing drugs, increasing competition and choices in the marketplace, and getting safe, effective, and more-affordable medicines into the hands of the people who need them.
- Senator Healthcare - Generic Drugs
If elected as a trustee, the campaign committee of Sen. Richard Durbin (IL) will be unconditionally awarded the funds pledged to this issue along with a letter requesting him to favorably consider passing S.142 - Preserve Access to Affordable Generics and Biosimilars Act.
|
- No trustee votes received.
|
| Poll Opening Date |
May 08, 2023 |
| Poll Closing Date |
May 14, 2023 |
|
|
